mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders.

Orphanet J Rare Dis · 2017 · PMC5348752 · PMID 28288694

Europe PMC DOI

hedged sentence

0.1100

closest p · 2.2× alpha

0.1100

boldest claim

The sentences

failed to reach statistical significancep = .11not close (p > 0.1)

In a recent, small, randomized trial of 23 children (ages 3 months to 12 years) with TSC, treatment with sirolimus decreased overall seizure frequency 41% over standard of care, but this change failed to reach statistical significance ( p = .11) [ 55 ].

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.